You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Adcetris

Showing 1 - 25 of 97
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Brentuximab Vedotin in Pediatric Hodgkin Lymphoma

Not yet recruiting
  • Hodgkin Lymphoma
  • Brentuximab Vedotin
  • (no location specified)
Jul 28, 2022

Diffuse Cutaneous Systemic Sclerosis Trial in London (Brentuximab Vedotin)

Recruiting
  • Diffuse Cutaneous Systemic Sclerosis
  • Brentuximab Vedotin
  • London, Ontario, Canada
    Rheumatology Clinic, St. Joseph's Health Care
Feb 3, 2022

Human Immunodeficiency Virus Trial in Chicago (brentuximab vedotin, Placebo, ART)

Recruiting
  • Human Immunodeficiency Virus
  • brentuximab vedotin
  • +2 more
  • Chicago, Illinois
    University of Illinois at Chicago
Jul 29, 2022

Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory

Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Pediatric Hodgkin Lymphoma
  • Brentuximab Vedotin (Genetical Recombination)
  • Tokyo, Japan
    Takeda Selected Site
Oct 11, 2022

Brentuximab Vedotin Intravenous Infusion "Untreated

Active, not recruiting
  • Untreated CD30-Positive Hodgkin's Lymphoma
  • Brentuximab vedotin (Genetical Recombination)
  • Tokyo, Japan
    Takeda Selected Site
Mar 24, 2022

Hodgkin Lymphoma Trial in Houston (Brentuximab vedotin, Doxorubicin Hydrochloride, Pembrolizumab)

Not yet recruiting
  • Hodgkin Lymphoma
  • Brentuximab vedotin
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 20, 2023

Hodgkin Lymphoma Trial in Valhalla (Brentuximab Vedotin, Doxorubicin, Vincristine)

Active, not recruiting
  • Hodgkin Lymphoma
  • Brentuximab Vedotin
  • +3 more
  • Valhalla, New York
    New York Medical College
Sep 27, 2022

Hodgkin Lymphoma Trial (pembrolizumab, brentuximab vedotin)

Active, not recruiting
  • Hodgkin Lymphoma
  • pembrolizumab
  • brentuximab vedotin
  • (no location specified)
Aug 18, 2022

Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult Trial in Leon (Brentuximab Vedotin 50 MG

Recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Brentuximab Vedotin 50 MG [Adcetris]
  • Leon, Guanajuato, Mexico
    Hospital Regional Alta Especialidad Bajio
Oct 24, 2022

Mycosis Fungoides Trial in Houston (Brentuximab vedotin)

Recruiting
  • Mycosis Fungoides
  • Brentuximab vedotin
  • Houston, Texas
    MD Anderson Cancer Center
Oct 14, 2022

T Cell Lymphoma Trial in Kansas City (Brentuximab Vedotin)

Withdrawn
  • T Cell Lymphoma
  • Brentuximab Vedotin
  • Kansas City, Kansas
    The University of Kansas Cancer Center, Westwood Campus
Feb 1, 2023

Hodgkin Lymphoma Trial in Valhalla (Brentuximab Vedotin, Allogeneic Stem Cell Transplantation, Reduced Intensity Conditioning)

Active, not recruiting
  • Hodgkin Lymphoma
  • Brentuximab Vedotin
  • +2 more
  • Valhalla, New York
    New York Medical College
Oct 24, 2022

CD30-Positive Neoplastic Cells Present, Malignant Mesothelioma Trial in Houston (Brentuximab Vedotin, Laboratory Biomarker

Recruiting
  • CD30-Positive Neoplastic Cells Present
  • Malignant Mesothelioma
  • Brentuximab Vedotin
  • Laboratory Biomarker Analysis
  • Houston, Texas
    M D Anderson Cancer Center
Jan 3, 2022

T-Cell Lymphoma Trial (Brentuximab vedotin, Pembrolizumab)

Not yet recruiting
  • T-Cell Lymphoma
  • (no location specified)
Jul 22, 2022

Leukemia Trial in Houston (Brentuximab Vedotin, 5-Azacytidine)

Terminated
Has Results
  • Leukemia
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Sep 7, 2022

Relapsed/Refractory Classical Hodgkin Lymphoma Trial in Goyang (Brentuximab vedotin)

Recruiting
  • Relapsed/Refractory Classical Hodgkin Lymphoma
  • Brentuximab vedotin
  • Goyang, Gyeonggi-do, Korea, Republic of
    Hyeon-Seok Eom
Feb 12, 2022

Diffuse Cutaneous Systemic Sclerosis Trial (Brentuximab vedotin)

Not yet recruiting
  • Diffuse Cutaneous Systemic Sclerosis
  • Brentuximab vedotin
  • (no location specified)
Apr 11, 2022

ALK+ Anaplastic Large Cell Lymphoma Trial in Wien (Brentuximab vedotin, Imatinib)

Terminated
  • ALK+ Anaplastic Large Cell Lymphoma
  • Wien, Austria
    Universitätsklinik f. Innere Medizin I, AKH Wien, Klinische Abte
Feb 15, 2022

Lymphoma, Large B-Cell, Diffuse Trial in Saint Louis, Columbus (Brentuximab vedotin, Lenalidomide)

Completed
  • Lymphoma, Large B-Cell, Diffuse
  • Saint Louis, Missouri
  • +1 more
Feb 16, 2022

Refractory Peripheral T-Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma Trial in Belgium, France (Brentuximab Vedotin -

Completed
  • Refractory Peripheral T-Cell Lymphoma
  • Relapsed Peripheral T-Cell Lymphoma
  • Brentuximab Vedotin - induction
  • +3 more
  • Antwerpen, Belgium
  • +38 more
Jan 9, 2023

Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Seattle (drug, other,

Recruiting
  • Recurrent Hodgkin Lymphoma
  • +3 more
  • Brentuximab Vedotin
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 4, 2022

Hodgkin Disease Trial in Worldwide (Brentuximab vedotin, Doxorubicin, Vinblastine)

Completed
Has Results
  • Hodgkin Disease
  • Brentuximab vedotin
  • +3 more
  • Aurora, Colorado
  • +13 more
Jun 17, 2022

HIV Infection, HIV-associated Hodgkin Lymphoma, Stage III Adult Hodgkin Lymphoma Trial in France (brentuximab vedotin,

Active, not recruiting
  • HIV Infection
  • +3 more
  • brentuximab vedotin
  • +3 more
  • Clamart, France
  • +5 more
Aug 11, 2022

Recurrent Classic Hodgkin Lymphoma Trial in Duarte (Brentuximab Vedotin, Nivolumab)

Recruiting
  • Recurrent Classic Hodgkin Lymphoma
  • Brentuximab Vedotin
  • Nivolumab
  • Duarte, California
    City of Hope Medical Center
Feb 16, 2022

Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Duarte (Brentuximab Vedotin, Cyclosporine, Pharmacokinetic

Active, not recruiting
  • Recurrent Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Brentuximab Vedotin
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Feb 17, 2022